Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, ACC

BerGenBio ASA: Invitation to Third Quarter 2019 Results Presentation and Webcast


BERGEN, Norway, Nov. 7, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), will announce its results for the third quarter on Tuesday 19 November 2019. A presentation by BerGenBio's senior management team will take place at 10am CET at:

Arctic Securities
Haakon VIIs gate 5
Oslo

The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513

International Media Relations 

Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Lucy Featherstone, Carina Jurs,
Consilium Strategic Communications
[email protected]
+44 20 3709 5700

Media Relations in Norway 

Jan Petter Stiff, Crux Advisers
[email protected]
+47 995 13 891

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing Phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com  

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bergenbio-asa/r/bergenbio-asa--invitation-to-third-quarter-2019-results-presentation-and-webcast,c2955673

The following files are available for download:

https://mb.cision.com/Main/15728/2955673/1137013.pdf

Release

SOURCE BerGenBio ASA


These press releases may also interest you

at 15:05
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...

at 15:05
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that Martine Rothblatt PhD, JD, MBA, Chairperson and CEO of United Therapeutics, and inventor of SiriusXM Satellite Radio, will deliver the keynote address...

at 15:00
Beghou Consulting announced Thursday several additions to its executive team to support the company's technology innovation, product development and growth initiatives. Dan Cardinal, a Partner at Beghou, will become Chief Technology Officer. The...

at 15:00
Urban Wellness Group, a pioneering wellness provider, is proud to announce its official launch of new anti-aging and sleep enhancement treatments to southeast Portland. Dr. Jason Zabell and Dr. Andy Swanson set themselves apart by pairing over 30...

at 14:55
Peninsula Canada, a global leading HR and health & safety firm, committed to making a positive impact in the community, is proud to announce a partnership with SickKids Foundation, a leading charity dedicated to supporting The Hospital for Sick...

at 14:30
The "Global Immunoprecipitation Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to  ResearchAndMarkets.com's offering. The Global Immunoprecipitation Testing Market size is estimated...



News published on and distributed by: